WALTHAM, Mass., Sept. 21, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Martin Huber, M.D., to the position of Senior Vice President and Chief Medical Officer. Dr. Huber will report to Mary Lynne Hedley, Ph.D., President and COO of TESARO, and will lead the global medical development, medical affairs and pharmacovigilance & safety functions at TESARO. Dr. Huber most recently served as Vice President, Oncology Clinical Research, at Merck Research Laboratories.
"I am pleased to welcome Marty to TESARO at such a pivotal time for the company as we launch VARUBI™, expand the development of our lead anticancer product candidate, niraparib, and advance our first immunology-oncology agents into the clinic," said Mary Lynne Hedley. "Marty's deep oncology drug development experience and strong leadership skills will be invaluable to us as we work to provide transformative therapies to people facing cancer."
Dr. Huber has over 20 years of leadership experience in the biopharmaceutical industry. Prior to Merck he served in roles of increasing responsibility at Schering-Plough, Hoffmann-La Roche. and Rhone-Poulenc Rorer, where he led teams in the areas of oncology clinical development, drug safety and pharmacovigilance. He previously served as an assistant professor of oncology at the University of Texas MD Anderson Cancer Center. Dr. Huber received his M.D. from Baylor College of Medicine.
About TESARO
TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include statements regarding the planned launch VARUBI™, expansion of the niraparib development program, and the advancement certain immunology-oncology agents into the clinic. These forward-looking statements involve substantial risks and uncertainties that could cause actual performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the execution and completion of clinical trials, ongoing discussions with and actions by regulatory authorities, and other matters that could affect the timing of availability of data from or initiation of our clinical trials, uncertainties regarding regulatory approvals, uncertainties regarding certain expenditures, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2014.